Advertisement

Clinical QTc Assessment in Oncology

  • Margaret R. BrittoEmail author
  • Nenad Sarapa
Chapter

Abstract

Cardiac proarrhythmia due to drug-induced QTc interval prolongation is an important concern in oncology since novel therapies can result in prolonged survival of cancer patients already predisposed to cardiotoxicity, and a number of anticancer agents, such as some of the tyrosine kinase inhibitors, are known to cause this risk. While not specifically requested by the ICH E14 guidance, a certain degree of QTc assessment in preapproval trials has emerged as the regulatory expectation with novel anticancer agents, particularly those that are small molecule chemical entities. This chapter reviews the challenges of evaluating QTc effect in oncology and proposes three integrated approaches to QTc risk assessment of anticancer agents (i.e., a “classic ICH E14-type” scenario, a “front-loaded” scenario, and a “full-development” scenario), which can be customized to different development plans and be evaluated using quantitative outcome criteria.

Keywords

ECG Electrocardiogram Thorough QT Concentration-QT TQT Clinical trials Cardiac repolarization 

References

  1. Agin MA, Kazierad DJ, Abel R, Anziano R, Billing CB, Layton G, Mancuso J, Strieter D, Xu W, Blum RA, Jorkasky DK (2003) Assessing QT variability in healthy volunteers. J Clin Pharmacol 43:1028, Abstract #61Google Scholar
  2. Arsenic trioxide (Trisenox®) Prescribing Information. http://www.trisenox.com/hcp/trisenox-prescribing-information.pdf
  3. Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609–3615CrossRefPubMedGoogle Scholar
  4. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN (2001) The QT interval. Prog Cardiovasc Dis 43(5 suppl 1):1–45PubMedGoogle Scholar
  5. Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L (2009) Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib. Clin Cancer Res 15:7045–7052CrossRefPubMedGoogle Scholar
  6. Bhave M, Akhter N, Rosen ST (2014) Cardiovascular toxicity of biologic agents for cancer therapy. Oncology (Williston Park) 28:482–490Google Scholar
  7. Ceritinib (Zykadia™) Prescribing Information. http://www.pharma.us.novartis.com/product/pi/pdf/zykadia.pdf
  8. Chiu Y-L, LoRusso P, Hosmane B, Ricker JL, Awni W, Carlson DM (2014) Results of a Phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors. Cancer Chemother Pharmacol 73:213–217CrossRefPubMedGoogle Scholar
  9. Couderc J-P, Xiaojuan X, Zareba W, Moss AJ (2005) Assessment of the stability of the individual-based correction of QT interval for heart rate. Ann Noninvasive Electrocardiol 10:25–34CrossRefPubMedGoogle Scholar
  10. Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R (2008) Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer 44:494–500CrossRefPubMedGoogle Scholar
  11. Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296–313CrossRefPubMedGoogle Scholar
  12. Darpo B, Garnett C (2013) Early QT assessment—how can our confidence in the data be improved? Br J Clin Pharmacol 76:642–648CrossRefPubMedGoogle Scholar
  13. Darpo B, Nebout T, Sager PT (2006) Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 46:498–507CrossRefPubMedGoogle Scholar
  14. Darpo B, Sarapa N, Garnett C, Benson C, Dota C, Ferber G, Jarugula V, Johannesen L, Keirns J, Krudys K, Ortemann-Renon C, Riley S, Rogers-Subramaniam D, Stockbridge N (2014a) The IQ-CSRC prospective clinical Phase 1 study: “can early QT assessment using exposure response analysis replace the thorough QT study?”. Ann Noninvasive Electrocardiol 19:70–81CrossRefPubMedGoogle Scholar
  15. Darpo B, Garnett C, Benson CT, Keirns J, Leishman D, Malik M, Mehrotra N, Prasad K, Riley S, Rodriguez I, Sager P, Sarapa N, Wallis R (2014b) Cardiac Safety Research Consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward. Am Heart J 168:262–272CrossRefPubMedGoogle Scholar
  16. Darpo B, Benson C, Dota C, Ferber G, Garnett C, Green CL, Jarugula V, Johannesen L, Keirns J, Krudys K, Liu J, Ortemann-Renon C, Riley S, Sarapa N, Smith B, Stoltz RR, Zhou M, Stockbridge N (2015) Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther 97:326–335CrossRefPubMedGoogle Scholar
  17. de Jonge M, Verweij J (2008) QTc prolongation and/or oncology drug development: who’s in danger? Eur J Cancer 44:486–487CrossRefPubMedGoogle Scholar
  18. Deeken JF, Shimkus B, Liem A, Hill D, Gurtler J, Berghorn E, Townes L, Lu H, Trifan O, Zhang S (2013) Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors. Cancer Chemother Pharmacol 71:1473–1483CrossRefPubMedGoogle Scholar
  19. Ferber G (2014) Statistical considerations and methods. Presented at IQ-CSRC meeting Can QT Assessment in Early Clinical Development be used to replace the TQT Study—Presenting Results from the Prospective IQ-CSRC Clinical Study. Silver Spring, MD, 12 Dec 2014. http://www.cardiac-safety.org/wp-content/uploads/2014/12/1a.-Ferber-December14.pdf
  20. Fingert H, Varterasian M (2006) Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management. AAPS J 8:E89–E94CrossRefPubMedPubMedCentralGoogle Scholar
  21. Garg A, Li J, Clark E, Knott A, Carrothers TJ, Marier J-F, Cortes J, Brewster M, Visich J, Lum B (2013) Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemother Pharmacol 72:1133–1141CrossRefPubMedPubMedCentralGoogle Scholar
  22. Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornoe CW, Wang Y, Zhu H, Gobburu JV (2008) Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48:13–18CrossRefPubMedGoogle Scholar
  23. Graham RA, Chang I, Jin JY, Wang B, Dufek MB, Ayache JA, Ezzet F, Zerivitz K, Low JA, Dresser MJ (2013) Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers. J Cardiovasc Pharmacol 61:83–89CrossRefPubMedGoogle Scholar
  24. Heath EI, Infante J, Lewis LD, Luu T, Stephenson J, Tan AR, Kasubhai S, LoRusso P, Ma B, Suttle AB, Kleha JF, Ball HA, Dar MM (2013) A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemother Pharmacol 71:565–573CrossRefPubMedPubMedCentralGoogle Scholar
  25. Hodges M (1997) Rate correction of the QT interval. Card Electrophysiol Rev 3:360–363CrossRefGoogle Scholar
  26. Holzgrefe H, Ferber G, Champeroux P, Gill M, Honda M, Greiter-Wilke A, Baird T, Meyer O, Saulnier M (2014) Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium. J Pharmacol Toxicol Methods 69:61–101CrossRefPubMedGoogle Scholar
  27. Hutmacher MM, Chapel S, Agin MA, Fleishaker JC, Lalonde RL (2008) Performance characteristics for some typical QT study designs under the ICH E-14 guidance. J Clin Pharmacol 48:215–224CrossRefPubMedGoogle Scholar
  28. ICH E14 Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. International Conference on Harmonization, October 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf
  29. ICH S7A Guideline: Safety pharmacology studies for human pharmaceuticals. International Conference on Harmonization, November 2000. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf
  30. ICH S7B Guideline: The non-clinical evaluation of the potential for delayed ventricular polarization (QT interval prolongation) by human pharmaceuticals. International Conference on Harmonization, May 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf
  31. ICH S9 Guideline: Nonclinical evaluation for anticancer pharmaceuticals. International Conference on Harmonization, October 2009. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf
  32. Johannesen L, Vicente J, Gray RA, Galeotti L, Loring Z, Garnett CE, Florian J, Ugander M, Stockbridge N, Strauss DG (2014) Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin Pharmacol Ther 95:501–508CrossRefPubMedGoogle Scholar
  33. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116:1582–1591CrossRefPubMedGoogle Scholar
  34. Joshi A (2010) Strategies to address drug-drug interactions and QTc concerns in the clinical development of biologics. Presented at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics in Atlanta, GAGoogle Scholar
  35. Kowey PR, Malik M (2007) The QT interval as it relates to the safety of non-cardiac drugs. Eur Heart J 9(suppl G):G3–G8CrossRefGoogle Scholar
  36. Krudys KM (2014) Regulatory decision-making for the assessment of ECG effects of new drugs: exposure-response analysis. Presented at IQ-CSRC meeting “Can QT Assessment in Early Clinical Development be used to replace the TQT Study—Presenting Results from the Prospective IQ-CSRC Clinical Study”, Silver Spring, MD, 12 Dec 2014. http://www.cardiac-safety.org/wp-content/uploads/2014/12/3.-krudys.pdf
  37. Kwong YL (2004) Arsenic trioxide in the treatment of haematological malignancies. Expert Opin Drug Saf 3:589–597CrossRefPubMedGoogle Scholar
  38. Liu J (2014) FDA’s analysis and interpretation of the IQ/CSRC clinical study. Presented at IQ-CSRC meeting “Can QT Assessment in Early Clinical Development be used to replace the TQT Study—Presenting Results from the Prospective IQ-CSRC Clinical Study”, Silver Spring, MD, 12 Dec 2014. http://www.cardiac-safety.org/wp-content/uploads/2014/12/2.-IQ-CSRC_FDA_20141210-Jiang-Liu.pdf
  39. Locatelli M, Criscitiello C, Esposito A, Minchella I, Goldhirsch A, Cipolla C, Curigliano G (2015) QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. Target Oncol 10:27–43CrossRefPubMedGoogle Scholar
  40. Lush RM, Patnaik A, Sullivan D, Papadopoulos KP, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher A (2012) A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. Cancer Chemother Pharmacol 70:567–574CrossRefPubMedPubMedCentralGoogle Scholar
  41. Morganroth J (2007) Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 81:108–113CrossRefPubMedGoogle Scholar
  42. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA (1991) Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 67:774–776CrossRefPubMedGoogle Scholar
  43. Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, Li X, Comisar W, Chodakewitz JA, Wagner JA, Iwamoto M (2009) A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 15:7077–7084CrossRefPubMedGoogle Scholar
  44. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
  45. Patterson S, Agin M, Anziano R, Burgess T, Chuang-Stein C, Dmitrienko A, Ferber G, Geraldes M, Ghosh K, Menton R, Natarajan J, Offen W, Saoud J, Smith B, Suresh R, Zariffa N (2005a) Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations: report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team. Drug Inf J 39:243–266Google Scholar
  46. Patterson S, Jones B, Zariffa N (2005b) Modeling and interpreting QTc prolongation in clinical pharmacology studies. Drug Inf J 39:437–445Google Scholar
  47. Piotrovsky V (2005) Pharmacokinetic-Pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 7:E609–E624CrossRefPubMedPubMedCentralGoogle Scholar
  48. Ponatinib (Iclusig®) Prescribing information. http://www.ariad.com/pdf/Iclusig-Prescribing-Information_Oct2014.pdf
  49. Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157:827–836CrossRefPubMedGoogle Scholar
  50. Rodriguez I, Erdman A, Padhi D, Christine E, Garnett CE, Zhao H, Targum SL, Balakrishnan S, Strnadova C, Viner N, Geiger MJ, Newton-Cheh C, Litwin J, Pugsley MK, Sager PT, Krucoff MW, Finkle JK (2010) Electrocardiographic assessment for therapeutic proteins—scientific discussion. Am Heart J 160:627–634CrossRefPubMedGoogle Scholar
  51. Rohatagi S, Carrothers TJ, Kuwabara-Wagg J, Khariton T (2009) Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs. J Clin Pharmacol 49:1284–1296CrossRefPubMedGoogle Scholar
  52. Russell T, Riley SP, Cook JA, Lalonde RL (2008) A perspective on the use of concentration-QTc modeling in drug development. J Clin Pharmacol 48:9–12CrossRefPubMedGoogle Scholar
  53. Sager PT (2014) How Does the CIPA Initiative Relate to the IQ-CSRC Project? Presented at IQ-CSRC meeting “Can QT Assessment in Early Clinical Development be used to replace the TQT Study—Presenting Results from the Prospective IQ-CSRC Clinical Study”, Silver Spring, MD, 12 Dec 2014. http://www.cardiac-safety.org/wp-content/uploads/2014/12/CSRC-IQ-Talk-SAGER-final.pdf
  54. Sager PT, Kowey P (2014) The thorough QT study: is its demise on the horizon? Ann Noninvasive Electrocardiol 19:1–3CrossRefPubMedGoogle Scholar
  55. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N (2014) Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 167:292–300CrossRefPubMedGoogle Scholar
  56. Sarapa N (2005) Digital 12-lead holter in the assessment of drug effects on cardiac repolarization. J Cardiol 38:293Google Scholar
  57. Sarapa N, Britto MR (2008) Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf 7:305–318CrossRefPubMedGoogle Scholar
  58. Sarapa N, Huang X, Varterasian M, Fingert H (2005) Risk management and eligibility criteria for QTc assessment in patients with advanced cancer. J Clin Oncol 23(16S, Part I of II):3047, ASCO Annual Meeting ProceedingsGoogle Scholar
  59. Shah RR (2002) Drug-induced prolongation of the QT interval—why the regulatory concern? Fundam Clin Pharmacol 16:119–124CrossRefPubMedGoogle Scholar
  60. Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG (2013) Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol 71:1599–1607CrossRefPubMedPubMedCentralGoogle Scholar
  61. Stockbridge N, Brown BD (2004) Annotated ECG waveform data at FDA. J Electrocardiol 37(suppl):63–64CrossRefPubMedGoogle Scholar
  62. Stockbridge N, Throckmorton DC (2004) Regulatory advice on evaluation of the proarrhythmic potential of drugs. J Electrocardiol 37(suppl):40–41CrossRefPubMedGoogle Scholar
  63. Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362–3371CrossRefPubMedGoogle Scholar
  64. Sun H, Chen P, Hunt J, Malinowski H (2004) Frequency of QT recording and reliability of QT prolongation assessments. Clin Pharmacol Ther 75:P48CrossRefGoogle Scholar
  65. Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J 34:1102–1111CrossRefPubMedGoogle Scholar
  66. Thertulien R, Manikhas GM, Dirix LY, Vermorken JB, Park K, Jain MM, Jiao JJ, Natarajan J, Parekh T, Zannikos P, Staddon AP (2012) Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol 69:341–350CrossRefPubMedGoogle Scholar
  67. Thomas SK, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu KL, Zimmerman TM, van de Velde H, Bandekar R, Puchalski TA, Qi M, Uhlar C, Samoylova OS (2014) Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol 73:35–42CrossRefPubMedGoogle Scholar
  68. Townsend C, Brown BS (2013) Predicting drug-induced QT prolongation and torsades de pointes: a review of preclinical endpoint measures. Curr Protoc Pharmacol 61:10.16.1–10.16.19Google Scholar
  69. Vandetanib Tablets Oncologic Drugs Advisory Committee (ODAC) Meeting Briefing Document, AstraZeneca, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM235092.pdf
  70. Varterasian M, Meyer M, Fingert H, Radlowski D, Asbury P, Zhou X, Healey D (2003) Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol 21:3378–3379CrossRefPubMedGoogle Scholar
  71. Varterasian M, Fingert H, Agin M, Meyer M (2004) Consideration of QT/QTc interval data in a Phase I study in patients with advanced cancer. Clin Cancer Res 10:5967–5970CrossRefPubMedGoogle Scholar
  72. Viskin S (1999) Long QT syndromes and torsades de pointes. Lancet 354:1625–1633CrossRefPubMedGoogle Scholar
  73. Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C (2014) Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a Phase Ib study. Cancer Chemother Pharmacol 74:1251–1260CrossRefPubMedPubMedCentralGoogle Scholar
  74. Yeh ETH (2006) Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 57:485–498CrossRefPubMedGoogle Scholar
  75. Zhang J, Stockbridge N (2011) Selection of the time points for a thorough QTc study. Drug Inf J 45:713–715CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Pharmacokinetics/PharmacodynamicsQuintiles, Inc.Overland ParkUSA
  2. 2.Clinical Sciences OncologyBayer Healthcare, Inc.WhippanyUSA

Personalised recommendations